Literature DB >> 21309260

Endometrial carcinomas with ambiguous features.

Robert A Soslow1.   

Abstract

Endometrial carcinomas are a heterogenous group of tumors that show variable histologies, molecular abnormalities and clinical outcomes. The idea of rigid distinctions between tumor types is appealing to pathologists, gynecologists, researchers and patients, but in a recent study where high grade endometrial carcinomas were reviewed by three experienced gynecologic pathologists, diagnostic agreement about tumor type was reached in only approximately one half of cases. In general, biologically and clinically validated diagnostic criteria are lacking for high grade endometrial carcinomas and for those that appear mixed epithelial. Until such criteria are developed, it remains important to define which morphologic patterns convey accurate clinical and biological information and which do not or might not. "Endometrial carcinomas with ambiguous features," the focus of this review, are tumors with comparatively uninformative morphologic features. Some publications indicate that gland forming and papillary endometrial carcinomas that appear morphologically low grade or ambiguous are really high grade. There are also indications that high grade endometrial carcinomas are biologically heterogeneous and that the morphologic clues we currently use to distinguish one subtype from another fail to correlate with biological data. Many tumors that appear morphologically mixed are, in fact, not biologically or clinically confused: most represent biologically "pure" tumors with variant morphology. Interesting associations between the presence of Lynch Syndrome (hereditary nonpolyposis colorectal carcinoma syndrome) and ambiguous morphology have been discussed in the literature. An apparent relationship between morphologic ambiguity and malignant mixed Müllerian tumor (MMMT) also exists. The identity of some morphologically ambiguous endometrial carcinoma can be elucidated with immunohistochemistry or other ancillary techniques at present, but the nature of many still remains undefined. This review presents the concept of morphologically ambiguous endometrial carcinomas, proposes morphological gold standard diagnostic criteria for tumors that are not ambiguous (an effort that helps define tumors that are ambiguous), provides a relevant literature review and offers practical guidance for sorting through diagnostically challenging cases.

Entities:  

Mesh:

Year:  2010        PMID: 21309260     DOI: 10.1053/j.semdp.2010.09.003

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  23 in total

1.  Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.

Authors:  Yaser R Hussein; Britta Weigelt; Douglas A Levine; J Kenneth Schoolmeester; Linda N Dao; Bonnie L Balzer; Georgia Liles; Beth Karlan; Martin Köbel; Cheng-Han Lee; Robert A Soslow
Journal:  Mod Pathol       Date:  2014-11-14       Impact factor: 7.842

2.  Lynch Syndrome Associated With PMS2 Mutation: Understanding Current Concepts.

Authors:  Shuchi Gulati; Shanna Gustafson; Hamed A Daw
Journal:  Gastrointest Cancer Res       Date:  2011-09

Review 3.  The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Authors:  Emily A Goebel; August Vidal; Xavier Matias-Guiu; C Blake Gilks
Journal:  Virchows Arch       Date:  2017-12-12       Impact factor: 4.064

Review 4.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

5.  Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.

Authors:  Martin Köbel; Bo Meng; Lien N Hoang; Noorah Almadani; Xiaodong Li; Robert A Soslow; C Blake Gilks; Cheng-Han Lee
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

6.  The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.

Authors:  Oluwole Fadare; Katja Gwin; Mohamed M Desouki; Marta A Crispens; Howard W Jones; Dineo Khabele; Sharon X Liang; Wenxin Zheng; Khaled Mohammed; Jonathan L Hecht; Vinita Parkash
Journal:  Mod Pathol       Date:  2013-03-22       Impact factor: 7.842

7.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

8.  Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus.

Authors:  Bojana Djordjevic; Shannon Westin; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2012-12-01

9.  Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.

Authors:  Salwa Bakhsh; Mary Kinloch; Lien N Hoang; Robert A Soslow; Martin Köbel; Cheng-Han Lee; Jessica N McAlpine; Melissa K McConechy; C Blake Gilks
Journal:  Histopathology       Date:  2015-12-17       Impact factor: 5.087

Review 10.  Type I and II endometrial cancers: have they different risk factors?

Authors:  Veronica Wendy Setiawan; Hannah P Yang; Malcolm C Pike; Susan E McCann; Herbert Yu; Yong-Bing Xiang; Alicja Wolk; Nicolas Wentzensen; Noel S Weiss; Penelope M Webb; Piet A van den Brandt; Koen van de Vijver; Pamela J Thompson; Brian L Strom; Amanda B Spurdle; Robert A Soslow; Xiao-ou Shu; Catherine Schairer; Carlotta Sacerdote; Thomas E Rohan; Kim Robien; Harvey A Risch; Fulvio Ricceri; Timothy R Rebbeck; Radhai Rastogi; Jennifer Prescott; Silvia Polidoro; Yikyung Park; Sara H Olson; Kirsten B Moysich; Anthony B Miller; Marjorie L McCullough; Rayna K Matsuno; Anthony M Magliocco; Galina Lurie; Lingeng Lu; Jolanta Lissowska; Xiaolin Liang; James V Lacey; Laurence N Kolonel; Brian E Henderson; Susan E Hankinson; Niclas Håkansson; Marc T Goodman; Mia M Gaudet; Montserrat Garcia-Closas; Christine M Friedenreich; Jo L Freudenheim; Jennifer Doherty; Immaculata De Vivo; Kerry S Courneya; Linda S Cook; Chu Chen; James R Cerhan; Hui Cai; Louise A Brinton; Leslie Bernstein; Kristin E Anderson; Hoda Anton-Culver; Leo J Schouten; Pamela L Horn-Ross
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.